About: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
Creator	Lee, Young Yeo, Suyeon
Source	PMC
abstract	Cefiderocol (Fetroja(®)) is a siderophore cephalosporin and has demonstrated potent activity against extended-spectrum beta-lactamases producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii, Burkholderia cepacia, and Klebsiella pneumoniae. However, cefiderocol has limited activity against Gram-positive bacteria and anaerobes like Bacterodies fragilis. In the APEKS-cUTI study, 183 (73%) of 252 patients in the cefiderocol group versus 65 (55%) of 119 patients in the imipenem-cilastatin group achieved the composite outcome of clinical and microbiological eradication of Gram-negative bacteria (treatment difference of 18.58%; 95% CI 8.23–28.92, p = 0.0004) in complicated urinary tract infections (cUTIs). Cefiderocol was non-inferior to imipenem-cilastatin in cUTIs caused by Gram-negative bacteria such as E. coli, K. pneumoniae, P. aeruginosa, Proteus mirabilis, Enterobacter cloacae, Morganella morganii, and Citrobacter freundii. Cefiderocol required dose adjustment in patients with renal impairment and percentage of time that free drug concentrations above the minimum inhibitory concentration (%fT > MIC) best correlated with clinical outcomes. The most common adverse events with cefiderocol were gastrointestinal symptoms such as diarrhea, constipation, nausea, vomiting, or upper abdominal pain. Two phase III clinical trials, the CREDIBLE-CR study and the APEKS-NP study, investigated the efficacy and safety of cefiderocol for the treatment of pneumonia or cUTI, and both studies showed higher all-cause mortality associated with cefiderocol. Therefore, the use of cefiderocol should be limited only to the treatment of cUTIs from Gram-negative bacteria, especially in patients who have limited or no alternative treatment options.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.1007/s40261-020-00955-x
has license	no-cc
sha1sum (hex)	6f9c7ee8bae3d916347f59ba1bda1936c9bd4d86
schema:url	https://doi.org/10.1007/s40261-020-00955-x
resource representing a document's title	Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
has PubMed Central identifier	PMC7374078
schema:publication	Clin Drug Investig
resource representing a document's body	covid:6f9c7ee8bae3d916347f59ba1bda1936c9bd4d86#body_text
is schema:about of	named entity 'cephalosporin' named entity 'microbiological' named entity 'activity' named entity 'complicated' named entity 'group' named entity 'Cephalosporin' named entity 'limited' named entity 'limited' named entity 'Gram-negative bacteria' named entity 'study' named entity 'However' named entity 'Pathogens' named entity 'Cefiderocol' named entity 'cephalosporin' named entity 'anaerobes' named entity 'P. aeruginosa' named entity 'Citrobacter freundii' named entity 'carbapenem-resistant Enterobacteriaceae' named entity 'Gram-negative bacteria' named entity 'minimum inhibitory concentration' named entity 'Gram-positive bacteria' named entity 'gastrointestinal symptoms' named entity 'all-cause mortality' named entity 'Burkholderia cepacia' named entity 'MIC' named entity 'cefiderocol' named entity 'Cefiderocol' named entity 'Cefiderocol' named entity 'K. pneumoniae' named entity 'Gramnegative' named entity 'renal impairment' named entity 'imipenem' named entity 'siderophore' named entity 'morphological' named entity 'thigh' named entity 'antibiotic' named entity 'Morganella morganii' named entity 'hospital-acquired infections' named entity 'renal impairment' named entity 'P. aeruginosa' named entity 'neutropenic' named entity 'carbapenem' named entity 'pharmacokinetic' named entity 'aztreonam' named entity 'extensively drug-resistant' named entity 'APEKS' named entity 'pyelonephritis' named entity 'systemic antibiotics' named entity 'ESRD' named entity 'CFU' named entity 'Gram-negative' named entity 'P. aeruginosa' named entity 'renal impairment' named entity 'PTA' named entity 'cefiderocol' named entity 'pathogens' named entity 'A. baumannii' named entity 'carbapenem' named entity 'imipenem' named entity 'Cefiderocol' named entity 'cefiderocol' named entity 'nausea' named entity 'carbapenem' named entity 'infection' named entity 'B. cepacia' named entity 'renal impairment' named entity 'S. maltophilia' named entity 'metabolites' named entity 'microbiological' named entity 'nosocomial pneumonia' named entity 'Pseudomonas aeruginosa' named entity 'bactericidal' named entity 'MIC' named entity 'population pharmacokinetic' named entity 'infusion' named entity 'lung infection' named entity 'A. baumannii' named entity 'clinically significant' named entity 'P. aeruginosa' named entity 'anaerobes' named entity 'ceftazidime' named entity 'K. pneumoniae'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software